(ZLAB) Zai Lab Limited Business Model Canvas Research

Deciphera’s Qinlock gives Zai Lab a licensed precision oncology drug for gastrointestinal stromal tumors, adding another marketed asset to its rare-tumor and specialist-oncology base. It broadens the company’s commercial mix beyond one therapy class and supports deeper reach in hard-to-treat cancers.

• Licensed asset: Qinlock for GIST
• Adds one more marketed precision medicine
• Strengthens rare-tumor positioning

Zai Lab Limited relies on global pipeline licensors such as MacroGenics, Mirati, Five Prime, and Turning Point to bring in assets like odronextamab, repotrectinib, margetuximab, adagrasib, and bemarituzumab. This cuts discovery risk and speeds pipeline buildout by using late-stage, partner-backed molecules instead of starting from zero.

• Multiple originators spread risk
• Late-stage assets speed launches
• Broader pipeline without full R&D cost

Zai Lab Limited’s regulatory and market access work centers on NMPA filings, approvals, and post-approval commitments, then moves each drug into NRDL reimbursement and hospital listing. In China’s hospital-led system, that path matters: Zai Lab reported 2024 total revenues of $399.9 million, and access speed can directly shape uptake.

• Manage NMPA approvals
• Pursue NRDL reimbursement
• Secure hospital formulary listing

Zai Lab Limited uses medical affairs and pharmacovigilance to keep physicians engaged through scientific exchange, track safety after launch, and build real-world evidence for oncology and anti-infective products. This matters because post-marketing surveillance protects trust and supports adoption once products move from trials into everyday care.

• Scientific exchange supports physician confidence
• Safety monitoring reduces post-launch risk
• Real-world evidence helps sustain product use

Shanghai headquarters anchors Zai Lab Limited’s management and China operating footprint, while the China platform is the base for regulatory, commercial, and medical-affairs work across Mainland China and Hong Kong. This local setup matters because Zai Lab reported RMB 4.0 billion in revenue in 2024, and execution in China is tied to that market engine.

• Shanghai-based control center
• China regulatory execution hub
• Commercial and medical-affairs coordination
• Mainland China plus Hong Kong coverage

Zai Lab Limited depends on scientific and regulatory talent to run clinical development, manage filings, and secure market access across oncology and specialty care, where trial design and approval paths are often complex. This human capital is what turns pipeline assets into approved medicines, and it matters most in late-stage programs that must clear China, U.S., and other regulator reviews.

• Clinical development moves assets from trial to approval.
• Regulatory affairs reduce filing and review risk.
• Market access supports reimbursement after approval.
• Most critical in oncology and specialty care.

Zai Lab Limited’s precision and differentiated therapies are built around biomarker-led assets such as PARP, ROS1/TRK, KRAS G12C, PD-1, and EGFR programs, which support specialist prescribing and sharper clinical separation in hard-to-treat cancers. In 2025, the company reported revenue of about US$400 million, showing commercial traction from this focused model.

• Biomarker-driven programs
• Specialist prescribing
• Hard-to-treat disease focus
• US$400 million 2025 revenue

Zai Lab Limited’s drug and device mix combines pharmaceuticals with Optune, a medical device for oncology care, so the company can address more than one treatment path. That broader mix helps physicians choose between drug therapy and device-based care, and it makes Zai Lab Limited’s offer more useful across different cancer settings.

• Drugs plus Optune widen oncology options
• Supports different physician treatment choices
• Stronger fit across care pathways

Zai Lab Limited can build patient loyalty through education, access guidance, and follow-up support, which matters most for high-cost specialty drugs and device therapies. This cuts delays between diagnosis, prior authorization, and treatment start, where even a 1- to 2-week wait can hurt uptake.

Specialty medicines can exceed $100,000 a year, so navigation help reduces drop-off and supports adherence. It also gives Zai Lab a stronger service layer around complex therapies.

• Helps patients start treatment faster
• Reduces access and approval friction
• Supports adherence for high-cost therapies

Post-launch safety follow-up keeps Zai Lab Limited close to patients after approval through pharmacovigilance and real-world evidence tracking. That means faster adverse-event detection, stronger regulatory compliance, and better brand trust as safety data keep flowing long after launch.

• Tracks outcomes after approval

• Manages adverse events in real time

• Supports compliance and credibility

Distribution partners help Zai Lab Limited move biologics, oncology drugs, and Optune across hospitals and markets, while cold-chain logistics keep supply stable for temperature-sensitive therapies. This channel matters because continuity is tied to delivery speed, regulatory handling, and last-mile access in complex care settings.

• Supports cross-border and hospital delivery
• Protects supply for sensitive therapies

Zai Lab Limited uses clinical trial networks, congresses, and digital medical channels to build awareness, generate evidence, and educate physicians. These channels support pipeline assets before launch and after launch, helping move data from trials into real-world physician use.

• Builds awareness fast
• Supports evidence generation
• Drives physician education
• Covers pre- and post-launch

Neurology and psychiatry specialists are a key future customer segment for Zai Lab Limited because assets like KarXT target schizophrenia and other CNS disorders, widening demand beyond oncology. In China, the 2020 national epidemiology survey estimated 7.3% of adults had a mental disorder, and that patient pool supports later-stage uptake as the pipeline advances.

• Drives KarXT demand
• Builds CNS beyond oncology
• Links to large unmet need

Zai Lab Limited serves patients in Mainland China and Hong Kong who need specialty therapies, especially those treated in tertiary hospitals. Demand is driven by diagnosis, reimbursement, and physician recommendation; in Mainland China, 1.4 billion people and a heavy hospital-based care model keep access to high-value oncology and immunology drugs central to this segment.

• End users need specialty therapies
• Tertiary hospitals drive prescribing
• Reimbursement shapes uptake
• Physician guidance shapes demand

Zai Lab Limited’s cost structure includes upfront license fees, development milestones, and sales royalties for in-licensed assets. These payments rise as products advance and can become a meaningful drag on margins once global sales scale.

• Upfront fees secure access
• Milestones grow with progress
• Royalties rise with sales

Manufacturing, quality, and logistics stay a fixed cost base for Zai Lab Limited, because biologics, anti-infectives, and device-based therapies need validated supply chains, cold-chain handling, and hospital-grade compliance. GMP controls, batch release testing, and distribution reliability drive recurring spend, and cold-chain drugs must keep 2-8°C through delivery.

• GMP and batch testing
• Cold-chain and traceability
• Hospital procurement compliance

Qinlock (ripretinib) adds revenue from advanced gastrointestinal stromal tumor, a rare cancer with about 10 to 15 new cases per million people each year. As a specialist oncology drug, it fits Zai Lab Limited’s precision-medicine focus and supports higher-value, physician-led sales.

• Rare, specialist GIST market
• Precision oncology fit
• Physician-driven revenue stream

Zai Lab Limited can earn collaboration income from licensing, milestones, and royalties tied to development and commercialization deals. In 2025, these payments can scale as pipeline assets move through clinical stages and launch, adding non-product revenue on top of direct sales; in biopharma, milestone checks often range from single-digit millions to tens of millions per event.

• Upfront fees fund early deal value

• Milestones rise as assets advance

• Royalties grow after launches